left-arrow right-arrow pinterest facebook google_plus linkedin

ECOG-ACRIN EA3132

Status:

Recruiting | Phase II

Official Title:

Testing The Addition Of Chemotherapy Drug, Cisplatin, To Usual Radiation Therapy For Patients With Head And Neck Cancer

Study Purpose:

To compare two treatment approaches currently used after surgery for head and neck cancer. One approach is to administer radiation therapy alone.  A second approach is to administer radiation therapy along with the chemotherapy drug, cisplatin.

Interventions:

Before study initiation, a laboratory test to determine the genomic mutation of the TP53 gene is mandatory. This will be accomplished by testing small pieces of cancer tissue from prior surgery.

Group 1: Radiation therapy (usual approach group)

Group 2: Radiation therapy plus cisplatin (study group)

Key Participation Requirements:

Gender:

Female and Male

Age:

19 years and older

Diagnosis:

Squamous cell carcinoma of the head/neck

Verrucous carcinoma of the head/neck

Spindle cell carcinoma of the head/neck

Carcinoma NOS of the head/neck (oral cavity, oropharynx, hypopharynx or larynx)

Eligibility:

Pathologic stage III or IVA

Has had surgery to remove the primary tumor

No chemotherapy within 2 years of surgical removal of tumor

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Methodist Health System Trial Code:

ECOG-ACRIN EA3132

For more information, visit the U.S. National Library of Medicine clinical trial database.

To learn more about this clinical trial please contact us today!